Text Size

A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye

Baudouin C., Figueiredo F.C., Messmer E.M., Ismail D., Amrane M., Garrigue J.-S., Bonini S., Leonardi A.


  • 2017
  • European Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Quinze-Vingts National Ophthalmology Hospital, Paris, France; Pierre et Marie Curie University, Paris 6, Vision Institute, INSERM UMR968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France; Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany; Santen SAS, Evry, France; Campus Bio Medico, Università di Roma, Rome, Italy; Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022